Načítá se...
PD-L1 Inhibition with Avelumab for Metastatic Merkel Cell Carcinoma
INTRODUCTION: Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer that lacks durable responses to traditional chemotherapy. AREAS COVERED: After MCC was shown to be an immunogenic tumor, small trials revealed high objective response rates to PD-1/PD-L1 checkpoint inhibito...
Uloženo v:
| Vydáno v: | Expert Rev Clin Pharmacol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6360093/ https://ncbi.nlm.nih.gov/pubmed/29478343 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17512433.2018.1445966 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|